COGNITION THERAPEUTICS, INC.
Pittsburgh, PA · Founded 2007 · CIK 0001455365 · Biotech · Public
CT1812, a brain-penetrant small molecule therapeutic that selectively clears toxic beta amyloid oligomers from the brain
cogrx.com →- Grants
- $13M
- 15 awards
- Sector median: 1
- Raised
- $23M
- 8 Form D · Nov 2018
- 95 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 9 granted · 31 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201020122014201620182020
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $2,500,000 | |
| Private capital raised | Form D · SEC | $1,823,845 | |
| Private capital raised | Form D · SEC | $1,921,749 | |
| Private capital raised | Form D · SEC | $5,984,457 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel sigma-2 receptor modulators for the treatment of cognitive dysfunction | $298,527 | |
| Private capital raised | Form D · SEC | $3,470,072 | |
| Federal grant | Department of Health and Human Services · Phase I · New piperazines effecting Abeta oligomer displacement from neuronal receptors | $224,002 | |
| Federal grant | Department of Health and Human Services · Phase II · Target Engagement Biomarkers for Alzheimer's Therapeutics | $222,004 | |
| Private capital raised | Form D · SEC | $2,999,905 | |
| Federal grant | Department of Health and Human Services · Phase II · Target Engagement Biomarkers for Alzheimer's Therapeutics | $1,741,285 | |
| Federal grant | Department of Health and Human Services · Phase II · Structural variants of Abeta oligomer displacing small molecules | $224,147 | |
| Private capital raised | Form D · SEC | $2,409,575 | |
| Federal grant | Department of Health and Human Services · Phase II · Structural variants of Abeta oligomer displacing small molecules | $1,464,768 | |
| Federal grant | Department of Health and Human Services · Phase II · Target Engagement Biomarkers for Alzheimer's Therapeutics | $746,126 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimization of sigma-2 receptor modulators for the treatment of cognitive dysfunction | $2,126,690 | |
| Federal grant | Department of Health and Human Services · Phase II · Mechanism of action of oligomer-displacing Alzheimer investigation drug, CT1812:Receptor interactions and signaling pathways | $360,119 | |
| Federal grant | Department of Health and Human Services · Phase II · Target Engagement Biomarkers for Alzheimer's Therapeutics | $250,000 | |
| Private capital raised | Form D · SEC | $1,646,868 | |
| Federal grant | Department of Health and Human Services · Phase II · Structural variants of Abeta oligomer displacing small molecules | $730,417 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimization of sigma-2 receptor modulators for the treatment of cognitive dysfunction | $1,072,222 | |
| Federal grant | Department of Health and Human Services · Phase II · Mechanism of action of oligomer-displacing Alzheimer investigation drug, CT1812:Receptor interactions and signaling pathways | $699,266 | |
| Federal grant | Department of Health and Human Services · Phase II · Mechanism of action of oligomer-displacing Alzheimer investigation drug, CT1812:Receptor interactions and signaling pathways | $729,226 | |
| Federal grant | Department of Health and Human Services · Phase II · Human AME study of CT1812, a small molecule in phase 2 clinical trials for the treatment of Alzheimer's disease | $1,642,783 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1565 | RELMADA THERAPEUTICS, INC. | — | $33M |
| 1566 | CELLOLOGI, LLC | — | — |
| 1567 | AUXAGEN, INC. | — | — |
| 1568 | COGNITION THERAPEUTICS, INC. | — | $23M |
| 1569 | ASYSTBIO LABORATORIES, LLC | — | — |
| 1570 | REPROTOX BIOTECH, LLC | — | — |
| 1571 | Macromoltek | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Mark BreedloveDirector
- Susan CatalanoDirector · Executive Officer
- Aaron FletcherDirector
- Robert GailusDirector
- Franz HeftiDirector
- Nada JainDirector
- Kenneth MochDirector · Executive Officer
- Harold SaffersteinDirector · Executive Officer
- Stephen SandsDirector
- Irwin ScherDirector
- Peggy WallaceDirector
Patents
- Isoindoline Compositions And Methods For Treating Neurodegenerative Diseaseapplication
- Crystalline Forms Of 2-(TERT-BUTOXY)-4-(3-METHYL-3-(5-(METHYLSULFONYL)ISOINDOLIN-2-YL)BUTYL)PHENOL Fumarate Saltapplication
- Compositions And Methods For Treating Neurologic Diseasesapplication
- Isoindoline Compositions And Methods For Treating Neurodegenerative Diseasegranted
- Isoindoline Compositions And Methods For Treating Neurodegenerative Diseaseapplication
- Compositions For Treating Neurodegenerative Diseasesapplication
- Compositions And Methods For Treating Neurologic Diseasesapplication
- Compositions For Treating Neurodegenerative Diseasesgranted
- Compositions For Treating Dry Age-related Macular Degeneration (amd)application
- Isoindoline Compositions And Methods For Treating Neurodegenerative Diseasegranted
- Method Of Decreasing Amyloid Beta Monomer Levels In Patients With Cognitive Declineapplication
- Compositions For Treating Neurodegenerative Diseasesgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.